Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB announced that its rights issue was fully subscribed, raising approximately SEK 91 million before costs. The oversubscription allowed the company to allocate shares to its Japanese partner, Solasia Pharma K.K., strengthening its financial position and supporting its strategy to generate new clinical data for arfolitixorin, which is expected to enhance cancer treatment options.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company based in Gothenburg, Sweden, focusing on developing treatments for cancer patients. The company’s primary product is arfolitixorin, a drug aimed at improving the treatment outcomes for cancer patients worldwide.
Average Trading Volume: 839,451
Current Market Cap: SEK237.6M
For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.